Fullcircle Wealth LLC Purchases 776 Shares of Zoetis Inc. (NYSE:ZTS)

Fullcircle Wealth LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 11.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 7,322 shares of the company’s stock after buying an additional 776 shares during the quarter. Fullcircle Wealth LLC’s holdings in Zoetis were worth $1,208,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Deutsche Bank AG lifted its stake in Zoetis by 29.7% in the 4th quarter. Deutsche Bank AG now owns 2,888,974 shares of the company’s stock valued at $470,701,000 after purchasing an additional 661,287 shares during the last quarter. Eagle Global Advisors LLC boosted its stake in Zoetis by 47.3% in the 4th quarter. Eagle Global Advisors LLC now owns 19,416 shares of the company’s stock valued at $3,163,000 after purchasing an additional 6,239 shares during the period. EP Wealth Advisors LLC boosted its position in shares of Zoetis by 1.9% in the fourth quarter. EP Wealth Advisors LLC now owns 247,100 shares of the company’s stock valued at $40,260,000 after acquiring an additional 4,498 shares during the period. Colonial Trust Co SC increased its position in Zoetis by 0.9% during the fourth quarter. Colonial Trust Co SC now owns 13,998 shares of the company’s stock worth $2,281,000 after acquiring an additional 118 shares during the period. Finally, CoreCap Advisors LLC boosted its holdings in Zoetis by 13.5% in the 4th quarter. CoreCap Advisors LLC now owns 1,050 shares of the company’s stock valued at $171,000 after purchasing an additional 125 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on ZTS shares. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Finally, Piper Sandler lifted their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $213.56.

Zoetis Stock Performance

Shares of ZTS stock opened at $156.15 on Thursday. The firm has a market capitalization of $69.67 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The business’s 50-day moving average price is $157.64 and its 200-day moving average price is $166.61. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the previous year, the business earned $1.38 EPS. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.